About this trial
Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.
Eligibility criteria
Qualifiers
Ages 18-25 years
Body mass index (BMI) 25-50 kg/m²
Female
Disqualifiers
Currently pregnant or lactating
Current involvement in a weight loss program or current use of weight loss medication
Lost >5% of their body weight in the previous 3 months
Uncontrolled medical conditions that may pose a safety issue given the recommendations for the diet and unsupervised physical activity
Trial design
Treatments tested in this trial
- Integrated Lifestyle Intervention (ILI)
- Monitoring with digital tools
Treatment groups
Sponsors and collaborators
Virginia Commonwealth University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator